All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

FDA approves Innoviva's Nuzolvence (zoliflodacin) for uncomplicated urogenital gonorrhea following Ph3 trial success
Small molecule, infectious disease, antibiotic, gonorrhea, antimicrobial resistance - Read more

ImmunityBio's Anktiva (nogapendekin alfa inbakicept) receives EU conditional approval recommendation for non-muscle invasive bladder cancer
Protein therapy, cancer, interleukin-15 receptor agonist, bladder cancer, combination therapy, immunotherapy - Read more

FDA expands Johnson & Johnson's Akeega (abiraterone/niraparib) approval for BRCA2-mutated metastatic castration-sensitive prostate cancer
Small molecule, cancer, combination therapy, prostate cancer, BRCA2 mutations - Read more

Milestone Pharmaceuticals receives FDA approval for CARDAMYST (etripamil) nasal spray targeting paroxysmal supraventricular tachycardia
Small molecule, cardiovascular, calcium channel blocker, paroxysmal supraventricular tachycardia, nasal spray, self-administered - Read more

THE GOOD
Business Development & Partnerships

Zealand Pharma seeks brain-targeting obesity treatment partners, explores shuttle technology collaborations
Research collaboration, neurological, small molecule, drug discovery, blood-brain barrier - Read more

PRESENTED BY SCIENCE 2 SALES
Cold calling in the life sciences - free webinar!

By popular demand, we’re running two webinars on cold calling in the life sciences - same session but two different times for convenience!

We’ll be covering:
• Why cold calling is so powerful right now (hint: points at all the AI everywhere)
• What is (and isn't) cold calling
• When it's worth it (sometimes it's not!)
• Mindset, strategies, and the technical bits behind doing cold calling

And probably a bunch more things - also a special guest 👀

Email [email protected] to get your invite

✅ More Good News ✅

THE GOOD
Clinical Trials

Celcuity presents updated Ph3 results for gedatolisib targeting PI3K/AKT/mTOR pathway in advanced breast cancer
Small molecule, cancer, PI3K inhibitor, breast cancer, hormone receptor positive - Read more

Relay Therapeutics reports positive subset analysis for zovegalisib (RLY-2608) plus fulvestrant in breast cancer patients
Small molecule, cancer, PI3K inhibitor, breast cancer, combination therapy - Read more

Anixa Biosciences' alpha-lactalbumin vaccine shows positive Ph1 results for triple-negative breast cancer prevention
Vaccine, cancer, breast cancer vaccine, triple-negative breast cancer, alpha-lactalbumin target - Read more

Innovent Biologics' mazdutide (GLP-1/glucagon dual agonist) shows significant weight loss in Ph1b obesity trial in Chinese adolescents
Protein therapy, metabolic, GLP-1 receptor agonist, obesity, adolescent population - Read more

THE GOOD
Fundraises

CIRM approves $160M funding for regenerative medicine research and clinical trials
Regenerative medicine, gene therapy, cell therapy, rare disease, clinical-stage, preclinical - Read more

Tenaya Therapeutics raises $60M public offering, developing heart disease therapies
Cardiovascular, clinical-stage, heart disease, biotechnology - Read more

Zegenex raises $215K social-impact investment for chronic wound healing therapies
Small molecule, wound healing, diabetic foot ulcers, preclinical - Read more

Contineum Therapeutics raises $90M public offering, neuroscience inflammation immunology therapies
Clinical-stage, neurological, autoimmune, inflammation - Read more

THE GOOD
Market Reports

William Blair predicts biotech sector will outperform 2021-24 bear markets in 2026 outlook
Market outlook, strategic, financial, competitive - Read more

THE GOOD
Mergers & Acquisitions

Sobi acquires Arthrosi Therapeutics for $950M upfront, adding gout treatment pozdeutinurad to pipeline
Small molecule, metabolic disease, strategic, major transaction - Read more

Cycle Pharmaceuticals acquires struggling Applied Therapeutics for 8.8 cents per share after FDA rejection
Small molecule, rare disease, strategic, major transaction - Read more

THE GOOD
Regulatory

CDC reports COVID-19 vaccines reduced emergency visits 76% in young children amid FDA death probe
mRNA vaccine, infectious disease, regulatory, operational - Read more

Tenaya Therapeutics receives FDA clearance to resume TN-201 gene therapy trial after clinical hold lifted
Gene therapy, cardiovascular, regulatory, operational - Read more

THE GOOD
Strategic Plans

Eli Lilly shifts Inluriyo-Verzenio combo regulatory strategy to ESR1-mutated advanced breast cancer following Ph3 results
Small molecule, cancer, SERD, breast cancer, CDK4/6 inhibitor, ESR1 mutation - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Arcus Biosciences terminates domvanalimab TIGIT-targeting therapy following Ph3 trial failure in gastric and esophageal cancers
Antibody, cancer, monoclonal antibody, gastric cancer, TIGIT target, combination therapy - Read more

THE BAD
Mergers & Acquisitions

Cosette Pharmaceuticals terminates Mayne Pharma acquisition after Australian Treasurer blocks transaction, both parties dispute breach claims
Generic pharmaceuticals, strategic, major transaction, regulatory - Read more

THE UGLY
Regulatory

FDA plans black box warning for COVID-19 vaccines following investigation into potential child deaths
mRNA vaccine, infectious disease, regulatory, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here